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1. Introduction 
The development of proteasome inhibitors has been an 
outstanding case showing that irreversible inhibitors may provide 
unique advantages by forming long-lived ties with their target.[1] 
Depending on the degree of reversibility of this covalent 
interaction, the putative proteasome inhibitor may therefore 
display a prolonged interaction and therefore biological action. A 
prolonged interaction may be beneficial when the undesired 
proteasome activity is manifest for an extended period.[2,3] 
Together with covalently reacting kinase inhibitors, which 
contain Michael acceptor moieties, proteasome inhibitors are part 
of the important arsenal of presently available crucial anti-cancer 
drugs. Inhibition of the protein degradation pathway in this 
manner is currently an effective approach for treatment of blood 
cancers.[4,5] Increasingly, established proteasome inhibitors are 
evaluated as anti-inflammatory immunoproteasome inhibitors 
leading to new therapeutic strategies for treatment of auto-
immune diseases such as rheumatoid arthritis and multiple 
sclerosis [6,7] Recently, in collaboration with Groll et al., we 
have achieved selective inhibition of the immunoproteasome by 
crosslinking of the active site effected by a peptido sulfonyl 
fluoride ligand (PSF).[8]  
Most proteasome inhibitors contain a single electrophilic 
moiety capable of covalently interacting with the threonine active 
site residue.[9] For example, the Michael acceptor electrophile 
containing proteasome inhibitors, especially the vinyl sulfones 
containing ones have been subject of intense investigations 
(Scheme 1).[10] ***Rob, deze laatste zin vond reviewer 1 
difficult to understand, dus moeten we herschrijven.*** 
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The success of inhibition of the proteasome by formation of covalent bonds is a major victory 
over the long held-view that this would lead to binding the wrong targets and undoubtedly lead 
to toxicity. Great challenges are now found in uncovering ensembles of new moieties capable of 
forming long lasting ties. We have introduced peptido sulfonyl fluorides for this purpose. 
Tuning the reactivity of this electrophilic trap may be crucial for modulating the biological 
action. Here we describe incorporation of a vinyl moiety into a peptido sulfonyl fluoride 
backbone, which should lead to a combined attack of the proteasome active site threonine on the 
double bond and the sulfonyl fluoride. Although this led to strong proteasome inhibitors, in vitro 
studies did not unambiguously demonstrate the formation of the proposed 7-membered ring 
structure. Possibly, formation of a 7-membered covalent adduct with the proteosomal active site 
threonine can only be achieved within the context of the enzyme. Nevertheless, this dual 
warhead concept may provide exclusive possibilities for duration and selectivity of proteasome 
inhibition. 
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 Scheme 1. Mechanisms of covalent inhibition of the 
proteasome by vinyl sulfones, α-β-epoxyketones and α-
ketoaldehydes. The threonine depicted in red represents the 
N-terminal threonine of the proteasome. 
 
However, in contrast to serine proteases in which the 
attacking nucleophile on the peptide-amide bond is the 
hydroxyl of the serine residue present as part of the catalytic 
triad, in the proteasome the amino acid involved in scission 
of the peptide-amide bond is an N-terminal threonine 
residue. This N-terminal threonine residue contains two 
nucleophiles. As a consequence, very effective, and 
selective inhibition has been achieved by proteasome 
inhibitors having 'dual' warheads that is containing two 
electrophilic sites. This is reflected by the treatment of 
multiple myeloma in patients with the proteasome inhibitor 
carfilzomib containing both an epoxide and carbonyl 
electrophilic site, after previous treatment with bortezomib, 
which contains just one electrophilic site (Figure 1). In our 
opinion this justifies a quest for dual warhead containing 
inhibitors such as the one discussed in this research. 
 
Scheme 2. Mechanism of covalent inhibition of the 
proteasome by peptido sulfonyl fluorides (PSF)[8] and 
proposed mechanism for inhibition by peptido vinylsulfonyl 
fluorides (PVSF). The threonine depicted in red represents 
the N-terminal threonine of the proteasome. 
 
 
 
Figure 1. Structures of Bortezomib, Epxomicin and 
Carfilzomib. 
 
Inspired by the "dual' warhead approach we describe in this 
paper a new proteasome inhibitor concept in which a 
Michael electrophilic trap, is combined with a sulfonyl 
fluoride electrophile incorporated into a peptide sequence 
leading to a peptido vinylsulfonyl fluoride (PVSF). Both 
electrophilic traps may then interact with both nucleophilic 
amino and hydroxyl moieties, of the N-terminal threonine 
residue present in the active site of the proteasome. Other 
covalently interacting proteasome inhibitors, having two 
electrophilic sites including Epoxomicin (Figure 1) and the 
alpha keto-aldehyde warhead containing inhibitors, show a 
similar molecular mechanism of action (Scheme 1).[11,12] 
However, in the sulfone Michael acceptor containing 
proteasome inhibitors only the 4-position is reacting with the 
threonine nucleophile(s) (Scheme 1). 
2. Results and discussion 
2.1 Chemistry 
Here we propose the peptido vinylsulfonyl fluoride 
(PVSF) as a new and promising dual warhead system. It was 
expected that its molecular structure would allow a Michael 
reaction leading to a sulfene intermediate followed by an 
intramolecular reaction of the second nucleophile in the 
threonine residue leading to a seven-membered ring 
covalent adduct (Scheme 2).  
 
The synthesis of peptido vinyl sulfonyl fluorides involved 
employing vinylogous amino sulfonates, which are 
accessible from amino acid derived aldehydes as was 
described by Gennari et al. (Scheme 3).[13] Briefly, Cbz-
protected leucinol (2) was converted into the corresponding 
amino aldehyde (3) by a Swern oxidation. A Wittig-Horner 
reaction with ethyl diethylphosphoryl methanesulfonate 
afforded vinylsulfonate ester 6, which was cleaved by 
Bu4NI. The most efficient conversion of the resulting 
sulfonate salt (7) into the corresponding vinylsulfonyl 
fluoride (8) was achieved by using talFluor-M® [14] in the 
presence of a catalytic amount of triethylamine 
trihydrofluoride acting as both a proton and fluoride 
source.[15] Two PVSF proteasome inhibitors (10 and 11, 
respectively) were obtained after cleavage of the Cbz-group 
from 8 followed by a coupling reaction with Cbz-Leu2-OH 
and Cbz-Leu3-OH using BOP. 
 
 
 
Scheme 3. Synthesis of PVSF compounds 10 and 11. 
 
2.2 Biological evaluation 
 
Recently, we described and established the 
molecular mechanism of action of our peptido sulfonyl 
fluoride (PSF) proteasome protease inhibitors.[8] It was 
found that selective inhibition of the immunoproteasome 
occurred by ligand-induced cross-linking of the active site 
(Scheme 2). With respect to this, comparison with other 
warheads highlights the peptido sulfonyl fluoride as a 
promising motif for 5i targeting. **hier iets zeggen dat de 
PSF ook erg goed werkt voor 5c, nu lijkt het dat dit niet zo 
is*** The sequences of inhibitors 10 and 11 were chosen 
based on earlier results with our most potent PSF 
proteasome inhibitors 17 and 18 (IC50-values 89 nM and 18 
nM, respectively, Figure 2).[16] Evaluation of the 
proteasome inhibitory activity gave IC50-values of 218 nM 
and 99 nM for PVSF compounds 10 and 11, respectively 
(Figure 1). At first we were somewhat surprised by the 
diminished activity of the PVSF's as compared to PSF's 17 
and 18, respectively.  Although a PVSF may be more 
reactive than a PSF, the sulfonyl fluoride warhead part may 
occupy a less favourable P1' position because it is further 
positioned from the P1 side chain, leading a reduced 
inhibition. Therefore, we believe that by evaluating different 
amino acid sequences with the vinyl sulfonyl fluoride dual 
warhead, as was done with the sulfonyl fluoride 
warhead,[16] even lower IC50-values may be obtained. 
Figure 2. Inhibitory curves of human constitutive 
proteasome by PVSF's 10 and 11 and PSF's 17 and 18.  
 
To investigate whether the proposed formation within the 
enzyme of a 7-membered ring adduct could be observed by 
chemo-synthesis, in parallel, the reactivity of a simplified 
peptido vinylsulfonyl fluoride (8) was studied with H-Thr-
Val-N(H)Me (13) as a model of the threonine residue 
present in the catalytic site of the proteasome (Scheme 4). 
Since formation of a seven membered-ring is not a very 
favourable reaction and the threonine residue is an 
ambidextrous nucleophile, an entirely clean reaction was not 
expected. In addition, other residues of the catalytic site of 
the proteasome are absent, especially any basic residues, 
which may affect the relative nucleophilicity of the 
threonine nucleophiles and thereby the sequence of steps in 
the molecular mechanism of inhibition by this PVSF 
warhead. 
 
Scheme 4. Model reaction of a PVSF with a threonine 
containing dipeptide comprising the N-terminal proteasome 
site. The attempted base/ solvent combinations were DBU, 
Et3N or NMM in CH2Cl2 and DBU or Et3N in CH3CN. 
 
Although it was possible to observe two small peaks at m/z 
541.44 and 563.49, corresponding to the [M+H]+ and 
[M+Na]+ ions of the 7-membered ring containing molecule 
(13), (Scheme 4, for LCMS spectrum see supporting 
information) ***Rob evt. Meer uitleg hier ivm laatste punt 
reviewer 5*** we were unable to isolate this adduct after 
(silica gel) column chromatography and preparative HPLC. 
Attempts by varying the solvent (DCM or MeCN) of the 
reaction and base (DBU, Et3N or NMM) were also 
unsuccessful to increase product formation and subsequent 
isolation of a 7-membered ring structure. ***hier korte 
uitleg dat de gevonden massa ook de open ring had kunnen 
zijn indien een Thr1 nucleofiel de fluor substitueert, en dat 
dit niet voor de hand ligt omdat uit eigen bevindingen en uit 
de literatuur[17+18] blijkt dat bij vinyl sulfonyl fluoriden 
het nucleofiel altijd eerst aanvalt op de Michael acceptor. 
Indien het tweede nucleofiel niet zou aanvallen om de 7-ring 
te vormen, dan zou de open ring nog een sulfonyl fluoride of 
sulfonaat bij eventuele hydrolyse hebben, wat een andere 
massa zou hebben.*** 
Therefore, we felt that it was necessary to get some insight 
in the reactivity of the peptido vinylsulfonyl fluorides and to 
what extent the proposed -"in vivo", that is in the 
proteasome - 7-membered ring might be formed "in vitro". 
Instead of the amino-group nucleophile as present in the 
threonine dipeptide model, the much simpler benzyl amine 
was used in excess. A disubstituted compound (16) resulting 
from a Michael reaction and substitution at the sulfonyl 
fluoride moiety was expected (Scheme 5). Unexpectedly, 
only traces of 16 were detected using ESI-MS, and instead 
-sultam 15 was formed. A plausible mechanism of 
formation is a Michael reaction followed by an 
intramolecular -sultam formation. Indeed -sultam 
compounds have been prepared conveniently in the past by 
reaction of ethenesulfonyl fluoride with various amines.[19] 
In agreement with the literature the first step is probably a 
Michael reaction of the amine (scheme 5). [18] Since a 7-
membered ring is in general not easily accessible, its 
proposed formation in vivo may be challenging to mimic in 
vitro.  
Scheme 5. Reaction and proposed mechanism of β-sultam 
formation of vinylsulfonyl fluoride 8 with benzyl amine. 
3. Conclusions 
We have introduced a peptido vinylsulfonyl fluoride (PVSF) 
as a new dual warhead containing proteasome inhibitor, 
active in a concentration as low as 90 nM. In contrast to our 
recently described peptido sulfonyl fluoride inhibitors, 
(Scheme 2) in which the inhibitor is released from the 
proteasome leaving a crosslinked proteasome active site 
behind, the peptido vinylsulfonyl fluoride was proposed to 
give rise to the formation of a covalent 7-membered ring 
adduct. This adduct should result from reaction of both 
nucleophiles of the threonine active site residues with the 
electrophiles of the dual warhead. The presence of 
simultaneously two electrophilic sites, which can both react 
because of the "combined effort" of the nucleophiles in the 
proteasome threonine residue, might be beneficial for the 
selectivity of these novel proteasome inhibitors, which were 
somewhat less active than the earlier developed PSF's. 
Although there was an indication of formation of the 
proposed 7-membered ring structure we were unable to 
isolate it and achieve its synthesis "in vitro", which instead 
led to formation of a -sultam structure. To our knowledge, 
no other more complex unsaturated sulfonyl fluorides, 
similar to the ones, which are topic of this paper, have been 
described in the literature in reactions with nucleophiles 
leading to sultams. Clearly, elucidation of the mechanism of 
inhibition of the proteasome by these new dual warhead 
containing peptido vinyl sulfonyl fluorides awaits a 
crystallographic analysis of these inhibitors within the 
proteasome, which is an important aim for future research.  
4. Experimental 
All reagents were obtained from commercial sources and 
used without further purification. THF was distilled over 
LiAlH4. Petroleum ether used for column chromatography 
was the 40–60 °C fraction.  Peptide grade and HPLC grade 
solvents were purchased from Actu-All (Oss, The 
Netherlands). Solvents were evaporated under reduced 
pressure at 40°C. The capping solution used was a mixture 
of 0.5 M acetic anhydride, 0.125 M DiPEA and 0.015 M 
HOBt in NMP. Reactions were carried out at ambient 
temperature unless stated otherwise. Reactions in solution 
were monitored by TLC analysis on Merck pre-coated silica 
gel 60 F-254 (0.25 mm) plates. Spots were visualised by UV 
light and by heating plates after dipping in a ninhydrine 
solution or in chlorine gas and TDM solution.[20] Column 
chromatography was performed on Siliaflash P60 (40-63 
μm) from Silicycle (Canada). 1H NMR data were acquired 
on a Varian Mercury 300 MHz spectrometer, an Agilent 400 
MHz spectrometer or on Bruker Avance III 400 MHz and 
500 MHz spectrometers in CDCl3, DMSO-d6 or acetone-d6 
as solvent. Chemical shifts (δ) are reported in parts per 
million (ppm) relative to TMS (0.00 ppm) or to the solvent 
residual signal of DMSO-d6 (2.50 ppm). Coupling constants 
(J) are reported in Hertz (Hz). Splitting patterns are 
designated as singlet (s), doublet (d), triplet (t), multiplet 
(m), and broad (b). 13C NMR data were acquired on a Varian 
Mercury 300 MHz spectrometer at 75 MHz, an Agilent 400 
MHz spectrometer at 100 MHz or on Bruker Avance III 500 
MHz spectrometer at 126 MHz in CDCl3, DMSO-d6 or 
acetone-d6 as solvent. Some of the 
13C NMR spectra were 
recorded using the attached proton test (APT) pulse 
sequence. Chemical shifts (δ) are reported in parts per 
million (ppm) relative to the solvent residual signal, CDCl3 
(77.00 ppm), DMSO-d6 (39.52 ppm), or acetone-d6 (29.84 
ppm). 19F NMR data were acquired on an Agilent 400 MHz 
spectrometer at 376 MHz or on a Bruker Avance III 500 
MHz spectrometer at 471 MHz. 2D NMR data (HSQC, 
COSY, and TOCSY) were acquired on Varian Mercury 300 
MHz spectrometer, an Agilent 400 MHz spectrometer or on 
Bruker Avance III 400 MHz and 500 MHz spectrometers. 
High-resolution electrospray ionization (ESI) mass spectra 
were measured on a Bruker micrOTOF-Q II in positive or 
negative mode and calibrated with an ESI tuning mix from 
Agilent Technologies, or measured on a Jeol MStation JMS-
700 instrument using positive chemical ionization (CI+) or 
positive ion impact (EI+). Proteasome Enzymatic Assays 
were performed using the VIVAdetectTM 20S Assay Kit 
PLUS (Viva bioscience, UK) and a Clariostar microplate 
reader (BMG LABTECH, Germany). 
 
4.1. Cbz-Leucinal (3) 
To a stirred solution of oxalyl chloride (5.45 mL, 63.0 
mmol) in CH2Cl2 (100 mL), under N2 atmosphere and 
cooled at -78 °C, were subsequently added dropwise a 
solution of DMSO (9.0 mL, 126 mmol) in CH2Cl2 (20 mL) 
and a solution of Cbz-Leucinol (38.2 mmol)[8] in CH2Cl2 
(27 mL). After 10 min stirring at -78 °C a solution of DiPEA 
(40 mL, 230 mmol) in CH2Cl2 (100 mL) was added 
dropwise, and stirring was continued at -78 °C for 30 min. 
After warming up the mixture to rt, it was quenched with 
H2O (13 mL) while severely stirring. Et2O (300 mL) was 
added to the mixture and the organic layer was then washed 
with KHSO4 (1.0 M, 2x100 mL). The water layer was 
extracted with Et2O (1x100 mL) and the two organic layers 
were combined, dried over Na2SO4, and concentrated under 
reduced pressure, yielding Cbz-Leucinal (3) as a yellow oil 
(10.0 g, quantitative yield). The crude product was almost 
pure (TLC analysis) and was directly used in the Wittig-
Horner reaction. 1H NMR (500 MHz, CDCl3): δ 0.90 (dd, J 
= 9.1, 6.7 Hz, 6H, 2x CH3) , 1.34 (ddd, Jgem = 13.5, Jvic = 
9.6, 5.0 Hz, 1H, CHaCH(CH3)2), 1.61 (ddd, Jgem = 13.5, Jvic = 
8.5, 4.8 Hz, 1H, CHbCH(CH3)2), 1.69 (m, 1H, CH(CH3)2), 
4.26 (m, 1H, NCH), 5.05 (s, 2H, CH2 (Cbz)), 5.18 (d, J = 6.4 
Hz, 1H, NH), 7.21 – 7.32 (m, 5H, C6H5 (Cbz)), 9.52 (s, 1H, 
C(O)H). 13C NMR (126 MHz, CDCl3): δ 21.9, 23.0 (CH3), 
24.6 (CH(CH3)2), 38.1 (CH2CH(CH3)2), 58.8 (NCH), 67.1 
(CH2 (Cbz)), 128.1, 128.5, 136.1 (C6H5 (Cbz)), 156.1 (C=O 
(Cbz)), 199.7 (C(O)H). HRMS m/z calculated for 
C14H20NO3 [M+H]
+: 250.1443, found: 250.1445.   
 
4.2. Ethyl methanesulfonate (4) 
Ethanol (6.40 mL, 110 mmol) was dissolved in dry CH2Cl2 
(400 mL) and cooled in an ice bath. N-methyl morpoline 
(22.0 mL, 200 mL) and methanesulfonyl chloride (7.70 mL, 
100 mmol) were added and the mixture was stirred for 30 
min. Then the ice bath was removed and the reaction was 
stirred overnight at room temperature. CH2Cl2 (200 mL) was 
added to the mixture and the organic layer was washed with 
an aqueous solution of KHSO4 (1.0 M, 2 x 200 mL) and 
water (1 x 200 mL), dried over MgSO4 and concentrated, 
resulting in ethyl methanesulfonate (10 g, 80 mmol, 81 %) 
as a colorless oil. Characterization data were in agreement 
with the literature.[21] 
 
4.3. Ethyl diethylphosphorylmethanesulfonate (5) 
Ethyl methanesulfonate 4 (10 g, 80 mmol) was dissolved in 
dry THF (200 mL) and treated with a 2.5 Ϻ n-BuLi solution 
in hexanes (35 mL, 89 mmol) over 30 min at −78 °C. After 
15 min, diethylchlorophosphate (6.5 mL, 45 mmol) was 
added and the solution was stirred for 30 min at −78 °C and 
allowed to stir for 1 hour at −50 °C. The mixture was 
concentrated, the residue was diluted with water (100 mL) 
and extracted with CH2Cl2 (3 x 120 mL). The combined 
organic layers were dried over MgSO4 and concentrated. 
Purification of the crude by silica column by petroleum 
ether:ethyl acetate (1:1) as eluents delivered 5 as a colorless 
oil (6.5 g, 25 mmol, 56%).  Characterization data were in 
agreement with the literature.[22] 
 
4.4. Cbz-vsLeu-OEt (6) 
A stirring mixture of Wittig-Horner reagent 5 (6.5 g, 25 
mmol) and anhydrous THF (100 mL) was cooled at -78 °C 
under N2 atmosphere. A solution of n-Butyllithium in 
hexanes (2.5 M, 10.5 mL, 26.2 mmol) was added dropwise, 
and after 20 min Cbz-Leucinal (3) (7.5 g, 30 mmol) in 
anhydrous THF (25 mL) was slowly added. Stirring was 
continued for 45 min at -78 °C and overnight at rt. The 
reaction mixture was then concentrated in vacuo, quenched 
with H2O (450 mL) and extracted with CH2Cl2 (3 x 450 
mL). The combined organic layers were dried over 
anhydrous MgSO4 and concentrated to afford the crude 6. 
Purification by silica gel chromatography (20% EtOAc in 
petroleum ether) yielded compound 6 as a yellowish oil (6.1 
g, 17 mmol, 68% yield). 1H NMR (300 MHz, CDCl3): δ 
0.95 (d, J = 6.6 Hz, 6H, 2 x CH3), 1.36 (t, J = 7.1 Hz, 3H, 
OCH2CH3), 1.44 (t, J = 7.3 Hz, 2H, CH2CH(CH3)2), 1.63-
1.76 (m, 1H, CH(CH3)2), 4.14 (q, J = 6.5 Hz, 2H, 
OCH2CH3), 4.45 (br s, 1H, NCH), 4.68 (br d, 1H, NH), 5.11 
[s, 2H, CH2 (Cbz)], 6.30 (dd, JAB = 15.2 Hz, JAC = 1.3 Hz, 
1H, CHCCHB=CHAS), 6.79 (dd, JBA = 15.2 Hz, JBC = 5.3 Hz, 
1H, CHCCHB=CHAS), 7.32-7.39 (m, 5H, C6H5); 
13C NMR 
(75 MHz, CDCl3): δ 14.8 (OCH2CH3), 21.9, 22.6 
(CH(CH3)2), 24.6 (CH(CH3)2), 43.0 (CH2CH(CH3)2), 49.9 
(NCH), 67.0, 67.0 [OCH2CH3, CH2 (Cbz)], 124.4 
(CH=CHS), 128.0, 128.3, 128.5, 136.0 (C6H5 (Cbz)), 148.6 
(CH=CHS), 155.5 (C=O). HRMS m/z calculated for 
C17H24NO5S [M-H]
-: 354.1381, found: 354.1366. 
 
4.5. Cbz-vsLeu-ONBu4 (7) 
A solution of compound 6 (6.1 g, 17 mmol) and NBu4I (6.3 
g, 17 mmol) in acetone (400 mL) was stirred overnight 
under reflux. The reaction mixture was then concentrated in 
vacuo and coevaporated with CHCl3 (3x50 mL), yielding 
compound 7 as a dense yellow oil (11.3 g). TLC analysis 
showed that the crude product was pure enough for being 
used in the next step without further purification. 1H NMR 
(400 MHz, CDCl3): δ 0.88 (m, 6H, CH(CH3)2), 1.00 (t, J = 
7.3 Hz, 12H, 4 x CH3 (NBu4)), 1.42 (m, 10H, 
CH2CH(CH3)2, 4 x CH2CH3 (NBu4)), 1.65 (m, 9H, 4 x 
CH2CH2CH3 (NBu4), CH(CH3)2), 3.30 (m, 8H, 4 x NCH2 
(NBu4)), 4.37 (m, 1H, NCH), 4.61 (d, J = 9.1 Hz, 1H, NH), 
5.05 (q, J = 12.3 Hz, 2H, CH2 (Cbz)), 6.40 (dd, J = 15.3, 4.6 
Hz, 1H, CH=CHSO3), 6.48 (dd, J = 15.3, 1.1 Hz, 1H, 
CH=CHSO3), 7.34 (m, 5H, C6H5 (Cbz)). 
13C NMR (126 
MHz, CDCl3): δ 13.7 (CH3 (NBu4)), 19.7 (CH2CH3 (NBu4)), 
22.2, 22.8 (CH(CH3)2), 24.1 (CH2CH2CH3 (NBu4)), 24.6 
(CH(CH3)2), 44.4 (CH2CH(CH3)2), 49.4 (NCH), 58.9 (NCH2 
(NBu4)), 66.5 (CH2 (Cbz)), 127.9, 128.4, 136.6 (C6H5 
(Cbz)), 133.9 (CH=CHSO3), 134.6 (CH=CHSO3), 155.6 
(C=O). HRMS m/z calculated for C15H20NO5S [M-NBu4]
-: 
326.1068, found: 326.1055.   
 
4.6. Cbz-Leu-VSF (8) 
To a solution of compound 7 (4.8 g, 7.2 mmol) in dry 
CH2Cl2 (170 mL) was added XtalFluor-M® (3.72 g, 15.3 
mmol), under N2 atmosphere.  A catalytic quantity of 
Et3N∙3HF (59 µL, 360 µmol) was added to the mixture, 
which was stirred overnight under reflux. After destruction 
of residual XtalFluor-M® by addition of silica gel to the 
solution, the mixture was filtered and concentrated in vacuo. 
Purification by silica gel chromatography (eluent: CH2Cl2 / 
petroleum ether (2/1)), afforded peptido vinylsulfonyl 
fluoride 8 as a white solid (720 mg, 2.18 mmol, 30% yield). 
Mp = 120°C. 1H NMR (300 MHz, CDCl3): δ = 0.96 (d, J = 
6.6 Hz, 6H, CH(CH3)2), 1.47 [t, J = 7.4 Hz, 2H, 
CH2CH(CH3)2], 1.71 (m, 1H, CH(CH3)2), 4.53 (m, 1H, 
NCH), 4.72 (br d, 1H, NH), 5.13 [s, 2H, CH2 (Cbz)], 6.52 
(d, J = 15.3 Hz, 1H, CH=CHS), 7.06 (dd, JAX = 4.8 Hz, JAB 
= 15.3 Hz, 1H, CH=CHS), 7.37 (s, 5H, C6H5). 
13C NMR (75 
MHz, CDCl3): δ = 21.6, 22.6 (CH(CH3)2), 24.6 [CH(CH3)2], 
42.5 (CH2CH(CH3)2), 50.1 (NCH), 67.3 [CH2 (Cbz)], 121.7 
(d, J = 27.8 Hz, CH=CHS), 128.1, 128.3, 128.6 (C5H6), 
135.8 (Ar-C), 153.6 (CH=CHS), 155.5 (C=O); 19F NMR 
(471 MHz, CDCl3): δ = 60.4 (s). HRMS m/z calculated for 
C15H19FNO4S [M-H]
-: 328.1024, found: 328.1017.  
 
4.7. HCl·H-Leu-VSF (9) 
A stirred solution of compound 8 (75.8 mg, 0.23 mmol) in 
CH2Cl2 (2.3 mL) was put under N2 atmosphere. After 
addition of HBr in acetic acid (33% v/v, 1.4 mL) stirring 
was continued for 30 min at rt. Then the solvents were 
evaporated and the residue dissolved in H2O (3.5 mL). 
Dowex-Cl (2×8, 200 mg) was added and the solution was 
stirred for 5 min at rt. and then filtrated. The water layer was 
washed with EtOAc (2x3.5 mL), then concentrated in vacuo 
and coevaporated with toluene (3x5 mL), yielding HCl∙H-
Leu-VSF (9) as a yellowish solid (53.7 mg, 0.23 mmol, 
quantitative yield). The crude 9 was used directly in the 
synthesis of 10 and 11. 
 
4.8. Cbz-Leu3-VSF (10) 
To HCl salt 9 (43.3 mg, 0.187 mmol) were subsequently 
added BOP (86.7 mg, 0.196 mmol), Cbz-Leu2-OH[9] (70.8 
mg, 0.187 mmol), CH2Cl2 (5 mL), and DiPEA (69 µL, 0.393 
mmol). The mixture was stirred overnight at rt under N2. 
During the reaction, the pH was monitored (pH indicator 
paper) and kept to approximately 9 by adding additional 
DiPEA, if necessary. After evaporation of the solvent, the 
residue was dissolved in EtOAc (15 mL) and was washed 
with KHSO4 (1.0 M, 3×10 mL), and brine (10 mL). The 
organic layer was dried over Na2SO4 and concentrated. 
Purification with silica gel column chromatography (eluent: 
26% EtOAc in hexanes) afforded Cbz-Leu1-Leu2-Leu3-VSF 
(10) as a white solid (26.8 mg, 0.048 mmol, 26% yield). 1H 
NMR (300 MHz, CDCl3): δ =  0.85-1.01 [m, 18H, 3 x 
CH(CH3)2], 1.41-1.86 [m, 9H, 3 x CH2CH(CH3)2], 4.14 [m, 
1H, NCH (Leu1)], 4.38 [m, 1H, NCH (Leu2)], 4.74 [m, 1H, 
NCH (Leu3)], 5.11 [2d, J = 12.2 Hz, 2H, CH2 (Cbz)], 5.38 
[d, J = 5.0 Hz, 1H, NH (Leu1)], 6.60 [m, 2H, 2 x NH, (Leu2), 
CH=CHS], 7.00 [d, J = 8.1 Hz, NH (Leu3)], 7.05 (dd, JAX = 
4.5 Hz, JAB = 15.2 Hz, 1H, CH=CHS), 7.30-7.43 (m, 5H, 
C6H5); 
13C NMR (75 MHz, CDCl3): δ =  21.6, 21.7, 21.8, 
22.8, 24.8, 25.0  (CH2CH(CH3)2), 39.9, 40.8, 42.1 
(CH2CH(CH3)2), 48.0 (NCH
3), 52.3 (NCH2), 54.3 (NCH1), 
67.3 [CH2 (Cbz)], 121.7, 122.1 (d, J = 27.4 Hz, CH=CHS), 
127.9, 128.4, 128.6, 135.7 (C6H5), 153.3 (CH=CHS), 156.7 
[C=O (Cbz)], 171.5, 172.7 [C=O (Leu1,2)]; 19F NMR (376 
MHz, CDCl3): δ = 59.2 (s); HRMS m/z calculated for 
C27H43FN3O6S [M + H]
+: 556.2858, measured: 556.2857. 
 
4.9. Cbz-Leu4-VSF (11) 
Cbz-Leu3-OMe (550 mg, 1.0 mmol)[23] was dissolved in 
Tesser’s base (12.5 mL, mixture of NaOH (2.0 M), MeOH 
and dioxane, in proportion 1:5:14 (v/v/v)). After the mixture 
was stirred overnight at rt, it was neutralized to pH 7 (pH 
indicator paper) with KHSO4 (1.0 M). The dioxane was 
evaporated in vacuo and the mixture was acidified to pH 2 
(pH indicator paper) with KHSO4 (1.0 M). The water layer 
was extracted with EtOAc (2x30 mL). The organic layer 
was washed with H2O (50 mL) and with brine (40 mL), 
dried over anhydrous Na2SO4 and concentrated in vacuo, 
yielding Cbz-leu3-OH as a white solid (501 mg, 1.0 mmol, 
quantitative yield). Cbz-Leu3-OH was coupled to HCl·H-
Leu-VSF (9) using the procedure described in the synthesis 
of 10. The scale of this reaction was 0.23 mmol. Purification 
with silica gel column chromatography (eluent: 36% EtOAc 
in hexanes) afforded Cbz-Leu1-Leu2-Leu3-vsLeu4-F (11) as a 
white solid (51.8 mg, 0.077 mmol, 33% yield). 1H NMR 
(300 MHz, CDCl3): δ =  0.77-1.03 (m, 24H, 4 x CH(CH3)2), 
1.38-1.90 (m, 12H, 4 x CH2CH(CH3)2), 3.93 [m, 1H, NCH 
(Leu1)], 4.19, 4.38 [2 x m, 2H, 2 x NCH (Leu2,3)], 4.75 [m, 
1H, NCH (Leu4)], 5.14 [s, 2H, CH2 (Cbz], 5.20 [s, 1H, NH 
(Leu1)], 6.40, 7.06 [2d, J = 4.6 Hz, J = 7.3 Hz, 2H, NH 
(Leu2,3)], 6.68 (dt, JAB = 15.0 Hz, JAX = 2.0 Hz, JAF = 2.0 Hz, 
CH=CHS], 7.08 [m, 2H, CH=CHS, NH (Leu4)], 7.29-7.43 
(m, 5H, C6H5); 
13C NMR (75 MHz, DMSO-d6): δ = 21.2, 
21.5, 21.6, 21.7, 22.9, 23.0, 24.2 (CH2CH(CH3)2), 40.2, 
40.6, 41.1 (CH2CH(CH3)2), 47.6 [NCH (Leu
4)], 51.1, 51.4 
[NCH (Leu2,3)], 53.3 [NCH (Leu1)], 65.4 [CH2 (Cbz)], 120.6 
(d, J = 25.5 Hz, CH=CHS), 127.6, 127.8, 128.3, 137.0 
(C6H5), 156.0 [C=O (Cbz)], 156.1 (CH=CHS], 171.7, 171.9, 
172.5 [3 x C=O (Leu1,2,3)]; 19F NMR (376 MHz, CDCl3): δ = 
59.0 (s); HRMS m/z calculated for C33H54FN4O7S [M + H]
+: 
669.3698, measured: 669.3694.  
 
4.10. TFA.H-Thr-Val-NHMe (13) 
To a solution of Boc-valine (5.4 g, 23 mmol) was in CH2Cl2 
(140 ml) was added BOP (10.2 g, 23 mmol). DiPEA (8.8 ml, 
50 mmol) and subsequently methylamine (18.8 ml, 37.5 
mmol, 2.0 M in THF) were added. After 2 hours stirring at 
rt, the mixture was concentrated in vacuo. Ethyl acetate (400 
mL) was added and washed two times with KHSO4 (1.0 M, 
200 mL), two times with NaHCO3 (1.0 M, 200 mL) and 
with brine (100 mL). After drying over Na2SO4 and 
concentration in vacuo, column chromatography (ethyl 
acetate/hexane, 40/60) was performed to afford Boc-Val-
NHMe (12) as a white solid (3.6 g, 65%). Boc-Val-NHMe  
(0.7 g, 3.0 mmol) was dissolved in CH2Cl2 (14 ml) and TFA 
was added (14 ml). The solution as stirred at rt for a half 
hour after which the mixture was concentrated in vacuo and 
coevaporated with chloroform (3x 200 mL). To the crude 
TFA.H-Val-NHMe was added CH2Cl2 (20 ml), BOP (1.0 g, 
3.24 mmol), DiPEA (1.1 ml, 6.5 mmol) and Boc-Thr-OH 
(0.7 g, 3.0 mmol). After stirring at rt for 18 hours, the 
solvent was evaporated and KHSO4 (1.0 M, 250 mL) was 
added. After extraction with ethyl acetate (3x 100 mL), the 
organic layers were combined, dried over Na2SO4 and 
concentrated in vacuo. Crystallization from ethyl acetate 
afforded Boc-Thr-Val-NHMe (12) as a white solid (346 mg, 
32%).  1H NMR (300 MHz, CDCl3): δ = 0.94 (m, 6H, 
CH(CH3)2), 1.18 (d, J = 6.3 Hz, 3H, CH3CHOH), 1.46 (s, 
9H, C(CH3)3), 2.23 (m, 1H, CH(CH3)2), 2.82 (d, J = 4.4 Hz, 
3H, CH3NH),  3.32 (bs, 1H, OH), 4.08 (d,  J = 7.5 Hz, 1H, 
CHCHOH), 4.21 (bt, 1H, CHCH(CH3)2), 4.32 (m, 1H, 
CHOH), 5.51 (d, J = 6.4 Hz, 1H, BocNH), 6.16 (bd, 1H, 
NHCH3), 6.96 (m, 1H, NHCHCH(CH3)2). 
13C NMR (300 
MHz, CHCl3): δ = 17.8, 18.5 (CH(CH3)2), 19.2 
(CH3CHOH), 26.0 (CH3NH), 28.2 (C(CH3)3), 30.3 
(CH(CH3)2), 58.6, 58.8 (NCH (Val and Thr)), 67.3 (CHOH), 
80.2 (C(CH3)3), 156.3 (C=O (Boc)), 171.3, 171.9 
(CONHCH3, HOCHCHC=O). HRMS m/z calculated for 
C15H29N3NaO5 [M+Na]
+: 354.1999, found: 354.1986. Boc-
Thr-Val-NHMe (346 mg, 0.96 mmol) was dissolved in 
CH2Cl2 (2 mL) and TFA (2 mL), and the solution was 
stirred for 30 minutes at rt. Concentration in vacuo and 
coevaporation with chloroform (3x 20 mL) afforded the 
crude TFA.H-Thr-Val-NHMe (13), which was directly used 
in the next reaction. 
 
 -sultam 15 
PVSF 8 (50 mg, 0.15 mmol) was dissolved in CH2Cl2 (3 
mL) and treated with benzylamine (50 μL, 0.45 mmol) 
overnight at rt. Evaporation of the solvent and purification 
by silica gel column chromatography (eluent: gradient of 
hexanes/ethyl acetate (6/1 to 4/1) afforded both 
diasteroisomers of β-sultam 15 as white solids 
(diastereoisomer 1: 10 mg, 24 mol, 16%; diastereoisomer 
2: 3 mg, 7.2 mol, 5%). Major isomer: 1H NMR (500 MHz, 
CDCl3): δ =  0.76 (t, J = 7.8 Hz, 6H, CH(CH3)2), 1.11 (dd, J 
= 8.6, 4.4 Hz, 2H, CH2CH(CH3)2), 1.47 (m, 1H, CH(CH3)2), 
3.21 (m, 1H, SO2NCH), 3.78 (m, 2H, CH
aSO2, CHNCO2), 
3.95 (m, 1H, CHbSO2), 4.02 (d, J = 14.5 Hz, 1H, NCH
aAr), 
4.24 (bd, 1H, NH), 4.35 (d, J = 14.5 Hz, 1H, NCHbAr), 5.98 
(d, J = 12.3 Hz, 1H, ArCHa (Cbz)), 5.07 (dd, J = 12.3, 2.3 
Hz, 1H, ArCHb (Cbz)), 7.21 – 7.31 (m, 10H, 2x C6H5). 13C 
NMR (126 MHz, CDCl3) δ = 21.5, 23.2 (CH(CH3)2), 24.6 
(CH(CH3)2), 39.6 (CH2CH(CH3)2), 50.0 (CHNCO2, NCH2), 
50.9 (CHNSO2), 58.8 (CH2SO2), 66.9 (CH2 (Cbz)), 127.9, 
128.1, 128.2, 128.6, 128.7, 129.0, 134.9, 136.3 (C6H5), 
156.2 (C=O (Cbz)). HRMS m/z calculated for 
C22H28N2NaO4S [M+Na]
+ : 439.1662, found: 439.1645. 
 
4.12. Proteasome Enzymatic Assays for IC50 
Determination 
Enzyme activity was determined by monitoring the 
hydrolysis of the fluorogenic substrate Suc-LLVY-AMC for 
1 hour at room temperature. Fluorescence was measured at 
λexc = 360, λem = 460 nm. Point-measurements were 
performed with a 1 hour incubation of the enzyme with the 
inhibitors prior to substrate addition. MG132 was used as 
reference inhibitor (included in the assay kit). The enzyme 
solution (25 nM) was prepared by dilution of the supplied 
20S proteasome (1 mg/mL) in VIVA buffer. A 10 µM stock 
solution of the substrate was made by dissolving Suc-
LLVY-AMC (500 µg) in DMSO, which was diluted with 
VIVA buffer resulting in a 1.0 mM substrate solution. For 
the inhibitor stock solution (500 µM), the inhibitor (1.0 mg) 
was dissolved in DMSO. DMSO was used for the inhibitor 
dilutions. In a typical assay to each well was added enzyme 
solution (5 µL), inhibitor solution (4 µL), substrate solution 
(5 ul) and buffer (36 uL). Final concentrations in the wells 
were: enzyme: 2.5 nM; substrate: 10 mM; inhibitor: 0.4, 2, 
10, 50, 100, 200, 400, 800, 1600 and 8000 nM. For the no 
inhibitor controls DMSO was added instead of inhibitor 
solution, thereby maintaining a final concentration of 9% 
DMSO per well. The assays were performed in triplicate. 
The inhibitory activities of compounds were expressed as 
IC50 values. The values were obtained by plotting the 
percentage of enzymatic activity against the logarithm of the 
inhibitor concentrations and fitting the experimental data to 
the equation % Residual Activity = 100/(1+10^((LogIC50-
Log c (inhibitor))*HillSlope))) using GraphPad Prism 
software. 
Acknowledgements 
We thank Thijs Nell for the synthesis of compound 12 and 
Javier Sastre Toraño for providing some of the HRMS 
spectra. This paper is dedicated to the memory of Johan 
Cruijff (1947 – 2016). 
References and notes 
1 Guterman, L. C&EN. 2011, 89, 19-26. 
2 Mah, R.; Thomas, J. R.; Shafer, C. M. Bioorg. Med. Chem. 
Lett. 1998, 8, 333-338. 
3 Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. Nat. Rev. 
2011, 10, 307-317. 
4 Richardson, P. G.; Hideshima, T.; Anderson, K. C. Cancer 
Control. 2003, 10, 361-369. 
5 Demo, S. D.; Kirk, C. J.; Aujay, M. A.; Buchholz, T. J.; 
Dajee, M.; Ho, M. N.; Jiang, J.; Laidig, G. J.; Lewis, E. R.; 
Parlati, F.; Shenk, K. D.; Smyth, M. S.; Sun, C. M.; 
Vallone, M. K.; Woo, T. M.; Molineaux, C. J.; Bennet, M. 
K., Cancer Res. 2007, 67, 6383-6391. 
6 Muchamuel, T.; Basler, M.; Aujay, M. A.; Suzuki, E.; 
Kalim, K. W.; Lauer, C.; Sylvain, C.; Ring, E. R.; Shields, 
J.; Jiang, J.; Shwonek, P.; Parlati, F.; Demo, S. D.; 
Bennett, M. K.; Kirk, C. J.; Groettrup, M. Nat. Med. 2009, 
15, 781-787. 
7 Basler, M.; Mundt, S.; Muchamuel, T.; Moll, C.; Jiang, J.; 
Groettrup, M.; Kirk, C. J. EMBO Mol. Med. 2014, 6, 226 -
238. 
8 Dubiella, C.; Cui, H.; Gersch, M.; Brouwer, A. J.; Sieber, 
S. A.; Kruger, A.; Liskamp, R. M. J.; Groll, M. Angew. 
Chem. Int. Ed. 2014, 53, 11969-11973. 
9 Verdoes, M.; Florea, B. I.; van der Linden, W. A.; Renou, 
D.; van den Nieuwendijk, A. M. C. H.; van der Marel, G. 
A.; Overkleeft, H. S. Org. Biomol. Chem. 2007, 5, 1416-
1426. 
10 Kisselev, A. F.; Van der Linden, W. A.; Overkleeft, H. S. 
Chem Biol. 2012, 19, 99-115. 
11 Gräwert, M. A.; Groll, M. Chem. Comm. 2012, 48, 1364-
1378. 
12 Huber, E. M.; Groll, M. Angew. Chem. Int. Ed. 2014, 51, 
2-15 
13 Gennari, C.; Salom, B.; Potenza, D.; Williams, A. Angew. 
Chem. Int. Ed. 2014, 53, 11969-11973. 
14 L’Heureux, A.; Beaulieu, F.; Bennett, C.; Bill, D. R.; 
Clayton S.; LaFlamme, F.; Mirmehrabi, M.; Tadayon, S.; 
Tovell, D.; Couturier, M. J. Org. Chem. 2010, 75, 3401-
3411. 
15 The previously used fluorinating reagent DAST gave 
higher yields, but the reactions were less clean and 
purification of the sulfonyl fluoride was tedious. The use 
of XtalFluor-M® led to clean reactions and easy 
purifications by column chromatography. 
16 Brouwer, A. J.; Jonker, A.; Werkhoven, P.; Kuo, E.; Li, 
N.; Gallastegui, N.; Kemmink, J.; Florea, B. I.; Groll, M.; 
Overkleeft, H. S.; Liskamp, R. M. J. J. Med. Chem. 2012, 
55, 10995-11003. 
17 Dong, J.; Krasnova, L.; Finn, M. G.; Sharpless, K. B. 
Angew. Chem. Int. Ed. 2014, 53, 9430-9448. 
18 Krutak, J. J.; Burpitt, R. D.; Moore, W. H.; Hyatt, J. A. J. 
Org. Chem.  1979, 44, 3847-3858. 
19 Champseix, A.; Chanet, J.; Etienne, A.; Le Berre, A.; 
Masson, J.; Napierala, C.; Vessiere, R. Bull. Soc. Chim. 
France. 1985, 3, 463-472. 
20 von Arx, E.; Faupel, M.; Bruggen, M. J. J. Chromatogr. 
1976, 120, 224-228. 
21 Truce, W. E.; Vrencur, D. J. J. Org. Chem. 1970, 35, 
1226-1227. 
22 Otrubova, K.; Cravatt, B. F.; Boger, D. L. J. Med. Chem. 
2014, 57, 1079-1089. 
23 Tian, J.; Gao, W.-C.; Zhou, D.-M.; Zhang, C. Org. Lett. 
2012, 14, 3020-3023. 
Supplementary Material 
NMR data and IC50 determination data. 
